Search Results - "LEMING, Philip D"

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab by TOPALIAN, Suzanne L, SZNOL, Mario, LEMING, Philip D, LIPSON, Evan J, PUZANOV, Igor, SMITH, David C, TAUBE, Janis M, WIGGINTON, Jon M, KOLLIA, Georgia D, GUPTA, Ashok, PARDOLL, Drew M, SOSMAN, Jeffrey A, McDERMOTT, David F, STEPHEN HODI, F, KLUGER, Harriet M, CARVAJAL, Richard D, SHARFMAN, William H, BRAHMER, Julie R, LAWRENCE, Donald P, ATKINS, Michael B, POWDERLY, John D

“…Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of…”
Get full text

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer by Topalian, Suzanne L, Hodi, F. Stephen, Brahmer, Julie R, Gettinger, Scott N, Smith, David C, McDermott, David F, Powderly, John D, Carvajal, Richard D, Sosman, Jeffrey A, Atkins, Michael B, Leming, Philip D, Spigel, David R, Antonia, Scott J, Horn, Leora, Drake, Charles G, Pardoll, Drew M, Chen, Lieping, Sharfman, William H, Anders, Robert A, Taube, Janis M, McMiller, Tracee L, Xu, Haiying, Korman, Alan J, Jure-Kunkel, Maria, Agrawal, Shruti, McDonald, Daniel, Kollia, Georgia D, Gupta, Ashok, Wigginton, Jon M, Sznol, Mario

“…Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint…”
Get full text

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602) by SLINGLUFF, Craig L, LEE, Sandra, FENGMIN ZHAO, CHIANESE-BULLOCK, Kimberly A, OLSON, Walter C, BUTTERFIELD, Lisa H, WHITESIDE, Theresa L, LEMING, Philip D, KIRKWOOD, John M

“…This multicenter randomized trial was designed to evaluate whether melanoma helper peptides augment cytotoxic T lymphocyte (CTL) responses to a melanoma…”
Get full text

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab by Topalian, Suzanne L, Sznol, Mario, McDermott, David F, Kluger, Harriet M, Carvajal, Richard D, Sharfman, William H, Brahmer, Julie R, Lawrence, Donald P, Atkins, Michael B, Powderly, John D, Leming, Philip D, Lipson, Evan J, Puzanov, Igor, Smith, David C, Taube, Janis M, Wigginton, Jon M, Kollia, Georgia D, Gupta, Ashok, Pardoll, Drew M, Sosman, Jeffrey A, Hodi, F Stephen

“…Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of…”
Get full text

The utility of circulating tumor DNA analysis to identify BRAF mutations in malignant melanoma by Kirby, Eric, Leming, Philip D.

“…Abstract only e14539 Background: Circulating tumor DNA provides an opportunity to assess the genetic profile of a patient’s tumor without performing a tissue…”
Get full text

Inferior vena cava filters in the management of cancer-associated venous thromboembolism: a systematic review by Rachna Raman, Philip D. Leming, Manish Bhandari, Daniel Long, Michael B. Streiff

“…This study systematically reviews outcomes after inferior vena cava (IVC) filtration in cancer-associated venous thromboembolism (VTE). A comprehensive review…”
Get full text

An independent oncology second opinion program: 2020 pilot project by Leming, Philip D., Hunt, Jillian M., Herzog, Thomas J., Jazieh, Abdul-Rahman, Barrett, William

“…Abstract only 179 Background: The estimated number of new cancer cases in the United States in 2020 is 1.8 million with an estimated 606,000 deaths. The…”
Get full text

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit by Grossman, Douglas, Okwundu, Nwanneka, Bartlett, Edmund K, Marchetti, Michael A, Othus, Megan, Coit, Daniel G, Hartman, Rebecca I, Leachman, Sancy A, Berry, Elizabeth G, Korde, Larissa, Lee, Sandra J, Bar-Eli, Menashe, Berwick, Marianne, Bowles, Tawnya, Buchbinder, Elizabeth I, Burton, Elizabeth M, Chu, Emily Y, Curiel-Lewandrowski, Clara, Curtis, Julia A, Daud, Adil, Deacon, Dekker C, Ferris, Laura K, Gershenwald, Jeffrey E, Grossmann, Kenneth F, Hu-Lieskovan, Siwen, Hyngstrom, John, Jeter, Joanne M, Judson-Torres, Robert L, Kendra, Kari L, Kim, Caroline C, Kirkwood, John M, Lawson, David H, Leming, Philip D, Long, Georgina V, Marghoob, Ashfaq A, Mehnert, Janice M, Ming, Michael E, Nelson, Kelly C, Polsky, David, Scolyer, Richard A, Smith, Eric A, Sondak, Vernon K, Stark, Mitchell S, Stein, Jennifer A, Thompson, John A, Thompson, John F, Venna, Suraj S, Wei, Maria L, Swetter, Susan M

“…Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care. To develop…”
Get more information

Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing by Kashani-Sabet, Mohammed, Leachman, Sancy A, Stein, Jennifer A, Arbiser, Jack L, Berry, Elizabeth G, Celebi, Julide T, Curiel-Lewandrowski, Clara, Ferris, Laura K, Grant-Kels, Jane M, Grossman, Douglas, Kulkarni, Rajan P, Marchetti, Michael A, Nelson, Kelly C, Polsky, David, Seiverling, Elizabeth V, Swetter, Susan M, Tsao, Hensin, Verdieck-Devlaeminck, Alexandra, Wei, Maria L, Bar, Anna, Bartlett, Edmund K, Bolognia, Jean L, Bowles, Tawnya L, Cha, Kelly B, Chu, Emily Y, Hartman, Rebecca I, Hawryluk, Elena B, Jampel, Risa M, Karapetyan, Lilit, Kheterpal, Meenal, Lawson, David H, Leming, Philip D, Liebman, Tracey N, Ming, Michael E, Sahni, Debjani, Savory, Stephanie A, Shaikh, Saba S, Sober, Arthur J, Sondak, Vernon K, Spaccarelli, Natalie, Usatine, Richard P, Venna, Suraj, Kirkwood, John M

“…Therapy for advanced melanoma has transformed during the past decade, but early detection and prognostic assessment of cutaneous melanoma (CM) remain paramount…”
Get more information

Multivariate prognostic factors in metastatic uveal melanoma (UM) by Deeb, Ayham, Abdel Karim, Nagla, Leming, Philip D., Bhatt, Ananta, Namad, Tariq, Xie, Changchun, Hunt, Jillian, Correa, Zelia, Augsburger, James

“…Abstract only…”
Get full text

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy by Johnson, Mariah M, Leachman, Sancy A, Aspinwall, Lisa G, Cranmer, Lee D, Curiel-Lewandrowski, Clara, Sondak, Vernon K, Stemwedel, Clara E, Swetter, Susan M, Vetto, John, Bowles, Tawnya, Dellavalle, Robert P, Geskin, Larisa J, Grossman, Douglas, Grossmann, Kenneth F, Hawkes, Jason E, Jeter, Joanne M, Kim, Caroline C, Kirkwood, John M, Mangold, Aaron R, Meyskens, Frank, Ming, Michael E, Nelson, Kelly C, Piepkorn, Michael, Pollack, Brian P, Robinson, June K, Sober, Arthur J, Trotter, Shannon, Venna, Suraj S, Agarwala, Sanjiv, Alani, Rhoda, Averbook, Bruce, Bar, Anna, Becevic, Mirna, Box, Neil, E Carson, 3rd, William, Cassidy, Pamela B, Chen, Suephy C, Chu, Emily Y, Ellis, Darrel L, Ferris, Laura K, Fisher, David E, Kendra, Kari, Lawson, David H, Leming, Philip D, Margolin, Kim A, Markovic, Svetomir, Martini, Mary C, Miller, Debbie, Sahni, Debjani, Sharfman, William H, Stein, Jennifer, Stratigos, Alexander J, Tarhini, Ahmad, Taylor, Matthew H, Wisco, Oliver J, Wong, Michael K

“…Melanoma is usually apparent on the skin and readily detected by trained medical providers using a routine total body skin examination, yet this malignancy is…”
Get full text

Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 by Hodi, F. Stephen, Lee, Sandra J., McDermott, David F., Rao, Uma N. M., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip D., Puzanov, Igor, Kirkwood, John M.

“…Abstract only CRA9007 Background: CTLA-4 blockade and GM secreting tumor vaccine combinations demonstrate therapeutic synergy in multiple preclinical models…”
Get full text

Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608 by Hodi, F. Stephen, Lee, Sandra J., McDermott, David F., Rao, Uma N. M., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip D., Puzanov, Igor, Kirkwood, John M.

“…Abstract only CRA9007 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June, 1, 2013, and in the…”
Get full text

A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma (E1602) by Slingluff, Craig L., Lee, Sandra, Zhao, Fengmin, Chianese-Bullock, Kimberly A., Olson, Walter, Butterfield, Lisa H., Whiteside, Theresa, Leming, Philip D., Kirkwood, John M.

Get full text

Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial by Hodi, F. Stephen, Sznol, Mario, Kluger, Harriet M., McDermott, David F., Carvajal, Richard D., Lawrence, Donald P., Topalian, Suzanne Louise, Atkins, Michael B., Powderly, John D., Sharfman, William Howard, Puzanov, Igor, Smith, David C., Leming, Philip D., Lipson, Evan J., Taube, Janis M., Anders, Robert, Horak, Christine E., Kollia, Georgia, Gupta, Ashok Kumar, Sosman, Jeffrey Alan

“…Abstract only…”
Get full text

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis by Brahmer, Julie R., Horn, Leora, Gandhi, Leena, Spigel, David R., Antonia, Scott Joseph, Rizvi, Naiyer A., Powderly, John D., Heist, Rebecca Suk, Carvajal, Richard D., Jackman, David Michael, Sequist, Lecia V., Smith, David C., Leming, Philip D., Topalian, Suzanne Louise, Hodi, F. Stephen, Sznol, Mario, Harbison, Christopher, Kollia, Georgia, Gupta, Ashok Kumar, Gettinger, Scott N.

“…Abstract only…”
Get full text

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventative Services Task Force controversy by Johnson, Mariah M, Leachman, Sancy A, Aspinwall, Lisa G, Cranmer, Lee D, Curiel-Lewandrowski, Clara, Sondak, Vernon K, Stemwedel, Clara E, Swetter, Susan M, Vetto, John, Bowles, Tawnya, Dellavalle, Robert P, Geskin, Larisa J, Grossman, Douglas, Grossmann, Kenneth F, Hawkes, Jason E, Jeter, Joanne M, Kim, Caroline C, Kirkwood, John M, Mangold, Aaron R, Meyskens, Frank, Ming, Michael E, Nelson, Kelly C, Piepkorn, Michael, Pollack, Brian P, Robinson, June K, Sober, Arthur J, Trotter, Shannon, Venna, Suraj S, Agarwala, Sanjiv, Alani, Rhoda, Averbook, Bruce, Bar, Anna, Becevic, Mirna, Box, Neil, E Carson, William, Cassidy, Pamela B, Chen, Suephy C, Chu, Emily Y, Ellis, Darrel L, Ferris, Laura K, Fisher, David E, Kendra, Kari, Lawson, David H, Leming, Philip D, Margolin, Kim A, Markovic, Svetomir, Martini, Mary C, Miller, Debbie, Sahni, Debjani, Sharfman, William H, Stein, Jennifer, Stratigos, Alexander J, Tarhini, Ahmad, Taylor, Matthew H, Wisco, Oliver J, Wong, Michael K

“…Melanoma is usually apparent on the skin and readily detected by trained medical providers using a routine total body skin examination, yet this malignancy is…”
Get full text

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer by POPLIN, E. A, LORUSSO, P, LOKICH, J. J, GULLO, J. J, LEMING, P. D, SCHULZ, J. J, VEACH, S. R, MCCULLOCH, W, BAKER, L, SCHEIN, P

“…The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential. The objective of this randomized study was to…”
Get full text

Atypical herpes simplex (HSV) infection in a patient with Hodgkin's disease by Leming, P D, Martin, S E, Zwelling, L A

“…An atypical presentation of herpes simplex virus type 1 (HSV-I) in the form of nodular tongue lesions was documented by histologic and immunohistochemical…”
Get more information

Nonspecific corticosteroid therapy in patients receiving intra-arterial chemotherapy for hepatic metastases of colorectal origin by Janis, L W, Leming, P D, Leder, W

“…Cholestatic jaundice induced by hepatic intra-arterial 5-fluorodeoxyuridine (FUDR) demonstrated marked improvement in three patients following treatment with…”
Get more information